BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vila-Corcoles A, Ochoa-Gondar O, Hospital I, de Diego C, Satué E, Bladé J, Ansa X, Guzmán JA, Salsench E, Ramos F. Pneumococcal vaccination coverages among low-, intermediate-, and high-risk adults in Catalonia. Hum Vaccin Immunother 2016;12:2953-8. [PMID: 27454779 DOI: 10.1080/21645515.2016.1210744] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Nakamura A, Kawakami K, Wakana A, Folaranmi TA, Iino T. A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) revaccination coverage rate among elderly adults aged 65 and older and physician's attitude. Hum Vaccin Immunother 2020;16:2292-9. [PMID: 32045317 DOI: 10.1080/21645515.2020.1717184] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Vila-Córcoles A, Ochoa-Gondar O, de Diego C, Satué E, Vila-Rovira A, Aragón M. Pneumococcal vaccination coverages by age, sex and specific underlying risk conditions among middle-aged and older adults in Catalonia, Spain, 2017. Euro Surveill 2019;24. [PMID: 31339099 DOI: 10.2807/1560-7917.ES.2019.24.29.1800446] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
3 Vila-corcoles A, Hospital I, Ochoa-gondar O, Satue E, de Diego C, Vila-rovira A, Gómez-bertomeu F, Raga X, Aragón M. Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015–2016. Vaccine 2020;38:1170-80. [DOI: 10.1016/j.vaccine.2019.11.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Cillóniz C, Liapikou A, Martin-Loeches I, García-Vidal C, Gabarrús A, Ceccato A, Magdaleno D, Mensa J, Marco F, Torres A. Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia. PLoS One 2018;13:e0200504. [PMID: 30020995 DOI: 10.1371/journal.pone.0200504] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
5 Càmara J, Marimón JM, Cercenado E, Larrosa N, Quesada MD, Fontanals D, Cubero M, Pérez-Trallero E, Fenoll A, Liñares J, Ardanuy C. Decrease of invasive pneumococcal disease (IPD) in adults after introduction of pneumococcal 13-valent conjugate vaccine in Spain. PLoS One 2017;12:e0175224. [PMID: 28384325 DOI: 10.1371/journal.pone.0175224] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
6 Vila-Corcoles A, Ochoa-Gondar O, de Diego C, Satue E, Aragón M, Vila-Rovira A, Gomez-Bertomeu F, Magarolas R, Figuerola-Massana E, Raga X, Perez MO, Ballester F. Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study. BMC Infect Dis 2018;18:196. [PMID: 29699550 DOI: 10.1186/s12879-018-3096-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
7 Ochoa-Gondar O, Vila-Córcoles Á, de Diego C, Satué E, Vila-Rovira A, Aragón M. [Antipneumococcal vaccination in Catalonian adults: Vaccine coverages and adequacy to distinct guideline recommendations]. Aten Primaria 2018;50:553-9. [PMID: 29373143 DOI: 10.1016/j.aprim.2017.05.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Kawakami K, Nakamura A, Wakana A, Folaranmi TA, Iino T. A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older. Hum Vaccin Immunother 2020;16:1521-8. [PMID: 31799889 DOI: 10.1080/21645515.2019.1690332] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ochoa-Gondar O, Hospital I, Vila-Corcoles A, Aragon M, Jariod M, de Diego C, Satue E; EPIVAC Study Group. Prevalence of high, medium and low-risk medical conditions for pneumococcal vaccination in Catalonian middle-aged and older adults: a population-based study. BMC Public Health 2017;17:610. [PMID: 28662648 DOI: 10.1186/s12889-017-4529-8] [Reference Citation Analysis]
10 Moreno-fernández J, García-seco JA, Rodrigo EMO, Segura AMS, García-seco F, Muñoz-rodríguez JR. Vaccination adherence to influenza, pneumococcal and hepatitis B virus in adult type 1 diabetes mellitus patients. Primary Care Diabetes 2020;14:343-8. [DOI: 10.1016/j.pcd.2019.09.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 González-Díaz A, Càmara J, Ercibengoa M, Cercenado E, Larrosa N, Quesada MD, Fontanals D, Cubero M, Marimón JM, Yuste J, Ardanuy C. Emerging non-13-valent pneumococcal conjugate vaccine (PCV13) serotypes causing adult invasive pneumococcal disease in the late-PCV13 period in Spain. Clin Microbiol Infect 2020;26:753-9. [PMID: 31756452 DOI: 10.1016/j.cmi.2019.10.034] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
12 Càmara J, Grau I, González-Díaz A, Tubau F, Calatayud L, Cubero M, Domínguez MÁ, Liñares J, Yuste J, Pallarés R, Ardanuy C. A historical perspective of MDR invasive pneumococcal disease in Spanish adults. J Antimicrob Chemother 2021;76:507-15. [PMID: 33254238 DOI: 10.1093/jac/dkaa465] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
13 Deb A, Guggisberg P, Mutschler T, Owusu-Edusei K, Bencina G, Johnson KD, Ignacio T, Mathijssen D, Qendri V. Cost-effectiveness of the 15-valent pneumococcal conjugate vaccine for high-risk adults in Switzerland. Expert Rev Vaccines 2022. [PMID: 35220875 DOI: 10.1080/14760584.2022.2046468] [Reference Citation Analysis]
14 Bianchi FP, Stefanizzi P, Spinelli G, Mascipinto S, Tafuri S. Immunization coverage among asplenic patients and strategies to increase vaccination compliance: a systematic review and meta-analysis. Expert Rev Vaccines 2021;20:297-308. [PMID: 33538617 DOI: 10.1080/14760584.2021.1886085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]